Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Horizon Pharma Ord (HZNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,724,650
  • Shares Outstanding, K 167,626
  • Annual Sales, $ 1,056 M
  • Annual Income, $ -410,530 K
  • 36-Month Beta 0.94
  • Price/Sales 3.21
  • Price/Cash Flow 7.29
  • Price/Book 4.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.54
  • Number of Estimates 5
  • High Estimate 0.55
  • Low Estimate 0.53
  • Prior Year 0.29
  • Growth Rate Est. (year over year) +86.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.94 +21.74%
on 12/24/18
22.66 -3.62%
on 01/17/19
+2.08 (+10.53%)
since 12/18/18
3-Month
16.56 +31.88%
on 10/26/18
23.38 -6.59%
on 11/08/18
+2.75 (+14.41%)
since 10/18/18
52-Week
12.55 +74.02%
on 05/09/18
23.38 -6.59%
on 11/08/18
+6.63 (+43.59%)
since 01/18/18

Most Recent Stories

More News
Do Options Traders Know Something About Horizon Pharma (HZNP) Stock We Don't?

Investors need to pay close attention to Horizon Pharma (HZNP) stock based on the movements in the options market lately.

HZNP : 21.84 (-1.71%)
Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout

Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout....

HZNP : 21.84 (-1.71%)
Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy

Horizon Pharma's (HZNP) share price increases about 28% based on its business expansion plan and acquisitions.

HZNP : 21.84 (-1.71%)
MRK : 75.87 (+0.36%)
RHHBY : 32.6100 (+0.59%)
BMY : 50.12 (+1.05%)
AMPEL BioSolutions Announces Proof That A Novel Treatment Rapidly Eliminates Uric Acid Build Up in Gout Patients

AMPEL BioSolutions, a leading technology research firm based in Charlottesville, VA today announced the publication of new data in Arthritis Research and Therapy, co-authored by AMPEL Co-Founder Dr. Peter...

HZNP : 21.84 (-1.71%)
Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group

Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.

HZNP : 21.84 (-1.71%)
MYGN : 29.67 (+3.67%)
EDIT : 26.14 (-0.27%)
INO : 5.09 (+0.20%)
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid to Include Newborns

Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for RAVICTI(R)...

HZNP : 21.84 (-1.71%)
Horizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference

Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the 37th Annual J.P. Morgan Healthcare Conference. Timothy P. Walbert, chairman, president and chief...

JPM : 104.59 (+1.62%)
HZNP : 21.84 (-1.71%)
Horizon Pharma (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?

Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HZNP : 21.84 (-1.71%)
Investor Expectations to Drive Momentum within Mammoth Energy Services, Horizon Pharma Public, SBA Communications, International Flavors & Fragrances, WillScot, and Teekay Tankers -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mammoth Energy Services, Inc....

TNK : 1.06 (+1.92%)
HZNP : 21.84 (-1.71%)
WSC : 10.58 (+5.06%)
SBAC : 173.05 (-0.24%)
IFF : 138.06 (+1.89%)
TUSK : 22.77 (-1.00%)
Lannett Co Inc has the Best Relative Performance in the Pharmaceuticals Industry (LCI , COLL , HZNP , ZGNX , SUPN )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

COLL : 15.76 (-1.75%)
LCI : 7.65 (+2.14%)
HZNP : 21.84 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade HZNP with:

Business Summary

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases....

See More

Key Turning Points

2nd Resistance Point 22.52
1st Resistance Point 22.18
Last Price 21.84
1st Support Level 21.63
2nd Support Level 21.42

See More

52-Week High 23.38
Last Price 21.84
Fibonacci 61.8% 19.24
Fibonacci 50% 17.97
Fibonacci 38.2% 16.69
52-Week Low 12.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar